CPRX stock forecast and financial insights

Previous Close	23.27
1-Year Change	67.53%
6-Months Change	17.11%
3-Months Change	11.77%
Moving Avg (50d)	22.164
Moving Avg (200d)	19.479
ESG Rating	-
Exchange	NASDAQ

Market Cap.	2.48B
Beta (3-Years)	1.09
Revenue Growth (ttm)	81.69%
Net Profit Margin (ttm)	17.81%
Return On Assets (ttm)	15.01%
EPS (ttm)	0.53
PE Ratio (ttm)	43.91
Dividend Yield	%

Chart provided by TradingView

Glossary:

TTM: Trailing Twelve Months
ESG: Environmental, Social and Governance
EPS: Earnings Per Share

Summary of the Company's Financials

The company Fiscal Period is usually around December 31, each year.
The latest company financial statement is: 10-Q filed as of 11/08/2023. Link to the latest 10-Q.
Link to company's latest filings (source data):
Catalyst Pharmaceuticals, Inc. SEC Filings

Period Ending:	12/31/2024	09/30/2024
Common Share Oustanding	120,879,099	119,266,561
Revenue Growth (%)	6.79	5.99
Earnings Growth (%)	14.77	109.54
Gross Margin Ratio (%)	86	86.32
Operating Margin Ratio (%)	39.68	37.78
Return On Aseets Ratio (%)	19.25	18.5
Return On Equity Ratio (%)	22.52	21.61
Net Profit Margin (%)	33.33	31.01
Dividend Per Share	-	-
Dividend Yield (%)	-	-
Earnings Per Share Basic	1.38	1.25
Earnings Per Share Diluted	1.31	1.18
Price-Earnings Ratio	-	15.9
PE Growth Ratio	-	265.69
Current Ratio	5.17	5.11
Debt Ratio	0.15	0.14

CPRX : Latest Forecast as of 2025-04-04

Asset Description:	Catalyst Pharmaceuticals, Inc.
Predicted Direction:	Buy
Signal Strength:	Buy
Forecast Date:	2025-02-14 00:00:00

Use our backtest tool to build and save you strategy

Signal Strength

		Strong Buy
		Buy
		Neutral
		Sell
		Strong Sell

Manage your risk using stop Loss position below. How much are you afford to loose ?

Stop Loss Prices by Risk level :

2%	5%	7%	10%	15%	20%
22.805	22.107	21.641	20.943	19.78	18.616

** Base on the close Price 23.27 as of 2025-02-14 00:00:00

The forecast above is based on the AI algorithm SR. Check the forecast for others algorithms below.

Forecast Pattern-Driven Strategy Forecast Macro-Pattern Mix St. Forecast Macro-Driven Strategy

In Millions USD (except per share data; shares in Millions)

Period Ending:	12/31/2024	09/30/2024	06/30/2024	03/31/2024	12/31/2023
Revenues	491.73	460.48	434.48	411.35	398.2
Cost Of Goods & Services Sold	68.85	63.01	57.9	54.54	51.97
Gross Profit	422.89	397.47	376.57	356.81	346.24
Total Operating Expenses	227.76	223.5	290.7	278.48	259.42
Depreciation And Amortization	37.77	37.46	36.58	35.71	32.88
Selling General And Admin. Expenses	177.74	175.58	163.26	150.93	133.71
Research & Development	12.65	10.82	91.2	92.17	93.15
Other Operating Expenses	-0.4	-0.37	-0.34	-0.33	-0.32
Total Cost And Expenses	296.61	286.51	348.6	333.02	311.39
Operating Income	195.12	173.97	85.88	78.33	86.81
Interest Expense	-	-	-	-	-
Income Tax Expense	52.37	45.99	25.41	21.17	23.1
Profit Loss	163.89	142.8	68.15	65.12	71.41
Net Income for Non-Controlling Interest	-	-	-	-	-
Net Income	163.89	142.8	68.15	65.12	71.41
Average Number Of Shares Basic	118.46	118.93	118.18	116.81	106.28
Average Number Of Shares Diluted	124.94	125.41	124.66	123.4	113.75
Earnings Per Share Basic	1.38	1.25	0.59	0.6	0.68
Earnings Per Share Diluted	1.31	1.18	0.54	0.54	0.61
EBITDA	254.04	226.25	130.14	122	127.39
EBIT	216.26	188.79	93.56	86.29	94.51
EBT	216.26	188.79	93.56	86.29	94.51
Common Share Oustanding	120.88	119.27	118.52	118.03	107.12
Common Share Authorized	200	200	200	200	200

Period Ending:	12/31/2024	09/30/2024	06/30/2024	03/31/2024	12/31/2023
Assets	851.41	772.01	706.36	646.68	470.11
Current Assets	623.61	539	474.43	404.6	219.33
Cash And Cash Equivalents	517.55	442.33	375.69	310.41	137.64
account Receivables	65.48	58.27	57.17	60.49	53.51
Inventory	19.54	20.02	18.01	19.95	15.64
Non Current Assets	227.8	233.01	231.93	242.07	250.79
Property Plant And Equipment Net	1.35	1.38	1.23	1.31	1.2
Property Plant And Equipment Gross	2.47	2.39	2.13	2.12	1.92
Acc. Depreciation And Amortization PPE	1.12	1.01	0.9	0.81	0.72
Intangible Assets Excluded Goodwill	156.67	166.02	175.36	184.71	194.05
Liabilities	123.78	111.07	97.71	85.26	82.23
Current Liabilities	120.68	105.4	92.32	79.57	76.06
Account Payables And Accrued Liabilities	120.68	105.4	92.32	79.57	76.06
Account Payables	16.59	11.56	7.12	10.26	14.8
Accrued Liabilities Current	104.09	93.83	85.2	69.31	61.27
Non Current Liabilities	3.1	5.67	5.39	5.7	6.17
Stockholders Equity	727.63	660.94	608.66	561.41	387.88
Common Stock Value	0.12	0.12	0.12	0.12	0.11
Additional Paid In Capital	442.29	431.6	423.2	416.75	266.49
Retained Earnings	285.16	229.23	185.34	144.55	121.27
Acc. Other Comprehensive Income Loss Net Of Tax	0.06	-	-	-	0.01
Liabilities And Stockholders Equity	851.41	772.01	706.36	646.68	470.11

Period Ending:	12/31/2024	09/30/2024	06/30/2024	03/31/2024	12/31/2023
Net Cash Operating	239.81	224.58	196.84	163.46	143.6
Net Income	163.89	142.8	68.15	65.12	71.41
Depreciation And Amortization	37.77	37.46	36.58	35.71	32.88
Depreciation	0.4	0.37	0.34	0.33	0.32
Amortization	37.38	37.09	36.23	35.38	32.57
stock Based Compensation	22.25	21.33	20.72	19.61	14.25
change In Receivables	-11.96	-10.22	-14.38	-27.09	-43.07
change In Inventories	-3.9	-10.98	-7.26	-9.62	-4.74
change In Payables	1.8	6.97	2.7	6.87	10.82
Net Cash Investing	-0.56	-38.79	-131.34	-131.33	-293.5
Capital Expenditure	-0.56	-0.56	-0.37	-0.36	-0.23
Net Cash Financing	140.67	135.57	131.41	130.04	-10.86
Net Cash	379.92	321.36	196.91	162.16	-160.76
Start Cash	137.64	120.97	178.79	148.25	298.4
End Cash	517.55	442.33	375.69	310.41	137.64
Free Cash	239.25	224.02	196.47	163.1	143.37

Data are sourced from company financial statements 10-K,10-Q filed with U.S. Securities and Exchange Commission (SEC).
Some variables might not be found in the statements filed by the company. These are simply deduced from other variables when possible. The dot "." in front of some rows means the variable is not directly found in the statement and thus is deduced from other variables.
Check Catalyst Pharmaceuticals, Inc. financial statements for more details following the link below.

https://www.sec.gov/edgar/browse/?CIK=0001369568

Latest news on Catalyst Pharmaceuticals, Inc. are available by following this link.

Catalyst Pharmaceuticals, Inc. News

News feed will be added in the future. Please get in touch with us if you are a news feed provider.

Sector:	Health Care
Industry:	Biotechnology
Country:	United States

Summary of the Company's Financials

CPRX : Latest Forecast as of 2025-04-04

Use our backtest tool to build and save you strategy

Signal Strength

Stop Loss Prices by Risk level :

Profitability Ratios

Liquidity Ratios

Leverage Ratios

Market value ratios

Efficiency ratios

Statements

Ask ChatGPT ?

Get financial insights from latest company's financial statements

Want to know about our in-house AI models ?

Company Profile

Catalyst Pharmaceuticals, Inc.

Market Overview

Portfolio Reference	EQ505LO2W
Performance Over 3M	16.0%
Performance Over 6M	21.0%

Model Portfolios

Return Checker Tool

Our Best Portfolio

View the portfolio composition

Short-Term Signals

Exclusive Assets

Optimal Allocation

Trading Strategies

Market Projections

Summary of the Company's Financials

CPRX : Latest Forecast as of 2025-04-04

Use our backtest tool to build and save you strategy

Signal Strength

Stop Loss Prices by Risk level :

Profitability Ratios

Liquidity Ratios

Leverage Ratios

Market value ratios

Efficiency ratios

Statements

Ask ChatGPT ?

Get financial insights from latest company's financial statements

Subscribe Now !

Want to know about our in-house AI models ?

Company Profile

Catalyst Pharmaceuticals, Inc.

Market Overview